BIOSION INC has a total of 12 patent applications. Its first patent ever was published in 2018. It filed its patents most often in China, WIPO (World Intellectual Property Organization) and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals and biotechnology are INTERNAT DRUG DEV BIOTECH, DECIMMUNE THERAPEUTICS INC and APTEVO RES & DEVELOPMENT LLC.
# | Country | Total Patents | |
---|---|---|---|
#1 | China | 5 | |
#2 | WIPO (World Intellectual Property Organization) | 4 | |
#3 | EPO (European Patent Office) | 1 | |
#4 | Republic of Korea | 1 | |
#5 | United States | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations |
# | Name | Total Patents |
---|---|---|
#1 | Chen Mingjiu | 12 |
#2 | Tan Wei | 7 |
#3 | Zhang Zhengping | 1 |
#4 | Zhong Cathy Xiaoyan | 1 |
#5 | Zou Xiaofang | 1 |
#6 | Song Wei | 1 |
#7 | Xia Shukai | 1 |
#8 | Xu Hongjiang | 1 |
Publication | Filing date | Title |
---|---|---|
WO2021043221A1 | Antibodies binding tslp and uses thereof | |
WO2020232051A1 | Antibody binding csf-1r and use thereof | |
CN109053889A | A kind of anti-human PD1 monoclonal antibody and purposes | |
CN109053887A | A kind of anti-human CSF-1R monoclonal antibody and purposes | |
CN109053886A | Anti-human CSF-1R monoclonal antibody and purposes | |
CN109053888A | A kind of anti-human CSF-1R monoclonal antibody and application thereof | |
CN110709419A | ERBB2 antibodies and uses thereof |